Compounded Semaglutide vs Wegovy: Is It the Same Drug?

Ask the question literally and the answer is yes: compounded semaglutide and brand Wegovy both deliver semaglutide, the same engineered gut-hormone analogue, to the same GLP-1 receptors in the body. At the level of the molecule that does the work, there is no difference to find. The peptide that quiets appetite in a compounded vial is, in principle, the identical peptide that does so in a Wegovy pen.

But "is it the same drug" turns out to be the wrong question, or at least an incomplete one. A medication is not only its active molecule. It is also the manufacturing process that produced it, the testing that confirmed its identity and purity, the regulatory framework that stands behind it, the legal basis on which it was prescribed, and the price you pay for it. On every one of those dimensions, compounded semaglutide and brand Wegovy diverge — sometimes modestly, sometimes a great deal. This article walks through where they are genuinely equivalent, where they are not, and how to think about the difference without either dismissing compounding or romanticising it.

The part that is genuinely the same: the molecule and its mechanism

Semaglutide is a long-acting GLP-1 receptor agonist — a modified version of the natural hormone glucagon-like peptide-1, engineered to survive in the bloodstream for about a week rather than the two minutes native GLP-1 lasts. Daniel Drucker's 2018 synthesis of GLP-1 pharmacology in Cell Metabolism lays out the four core actions that make the hormone useful: it stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts centrally to enhance satiety (Drucker, 2018). The appetite effect — the one that matters most for weight — runs through the gut, the hypothalamus, and the brain's reward circuitry. Liselotte van Bloemendaal's 2014 imaging work showed that GLP-1 receptor activation specifically attenuates the reward system's response to food cues, the neurobiological basis of what patients call the quieting of "food noise" (van Bloemendaal et al., 2014). The fuller account of how this works sits in our complete guide to GLP-1 medications and, for semaglutide specifically, in how semaglutide works for weight loss.

None of that mechanism cares where the semaglutide was made. If a compounded preparation contains genuine semaglutide at the labelled dose, it will engage the same receptors and produce the same biological effect as the branded product. This is the legitimate kernel of truth in the marketing that surrounds compounded GLP-1 medications, and it is worth stating plainly so the rest of the article is not mistaken for alarmism. The molecule is the molecule.

The clinical evidence behind that molecule, however, was generated using the branded, FDA-approved product. The STEP 1 trial led by John Wilding, published in the New England Journal of Medicine in 2021, randomised 1,961 adults with overweight or obesity to once-weekly semaglutide titrated to 2.4mg or placebo, and found a mean weight loss of about 14.9% over 68 weeks against roughly 2.4% on placebo (Wilding et al., 2021). The STEP 4 trial led by Domenica Rubino showed that the effect depends on continuation: participants switched to placebo regained roughly two-thirds of their lost weight over the following year (Rubino et al., 2021). These are studies of a specific, standardised, quality-controlled product. The reasonable inference is that an accurately dosed compounded equivalent should behave similarly — but that is an inference, not a tested result, and the gap between them is exactly what the rest of this article is about.

What "compounded" actually means

Compounding is the preparation of a customised medication by a licensed pharmacy, a practice that long predates the modern pharmaceutical industry. It exists to serve real needs: a patient who cannot tolerate a dye in a commercial tablet, a child who needs a liquid version of a drug sold only as a capsule, a formulation a manufacturer does not make. In the United States, compounding pharmacies operate under two distinct frameworks, and the difference between them matters enormously for semaglutide.

• 503A pharmacies are traditional compounding pharmacies that prepare medications for individual patients on a patient-specific prescription basis. They are regulated primarily by state boards of pharmacy, with some federal oversight, but they are not required to meet the federal current Good Manufacturing Practice (cGMP) standards that govern commercial drug manufacturers.
• 503B outsourcing facilities are larger operations that can produce compounded medications in bulk, without a patient-specific prescription, and register with and are inspected by the FDA. They are required to follow cGMP, which is substantially more rigorous than the 503A framework — though still not identical to the full apparatus that governs an approved finished drug.

Both types of facility can legally produce compounded semaglutide under the right circumstances. But the quality, consistency, and oversight of what they produce can differ widely, and "compounded semaglutide" from a cGMP-compliant 503B facility is a meaningfully different proposition from the same phrase attached to a lightly regulated 503A operation — or, worse, an unlicensed seller operating outside either framework.

What brand Wegovy is

Wegovy is a finished pharmaceutical product that has passed through the entire FDA drug-approval process. That process includes large randomised controlled trials demonstrating safety and efficacy, inspection and approval of the specific manufacturing facilities, a standardised and fixed formulation, defined stability and impurity testing, validated supply-chain controls, and ongoing post-market surveillance for adverse events. Every Wegovy pen is intended to contain a verified quantity of pharmaceutical-grade semaglutide in a consistent formulation, manufactured by the company that developed the molecule and holds the data on it.

This is the distinction that the phrase "same active ingredient" tends to flatten. The approval does not merely certify the molecule; it certifies a whole system — the process that makes the molecule, the tests that confirm each batch, and the accountability that attaches if something goes wrong. A compounded preparation may contain the same molecule while sitting outside most of that system.

Brand Wegovy vs. compounded semaglutide, side by side

Dimension	Brand Wegovy	Compounded semaglutide
Active molecule	Semaglutide (GLP-1 receptor agonist)	Semaglutide — same molecule in principle, though some preparations use a salt form rather than the base (see below)
FDA approval & oversight	FDA-approved finished drug; full trial dossier, post-market surveillance	Not FDA-approved as a product. The pharmacy is licensed; the specific compound is not reviewed or approved by the FDA
Manufacturing standards	Commercial pharmaceutical cGMP at inspected facilities	Varies by facility: 503B follows cGMP and is FDA-inspected; 503A follows state-board rules and is not held to the same standard
Salt form vs. base	Semaglutide base, the form studied in trials and approved	Some compounders have used semaglutide sodium or semaglutide acetate (salt forms) the FDA has flagged as different substances not established as safe and effective
Legality / 503A–503B context	Marketed under standard FDA approval; legality not shortage-dependent	Legally permitted mainly when the brand is on the FDA shortage list; legal footing narrows once the shortage resolves
Dosing reliability	Fixed, verified dose in every pen; standardised titration steps	Depends on the pharmacy's quality control; vial-and-syringe dosing adds a measurement step and room for error
Cost (approximate)	Often around $1,300+ per month at list price without insurance; manufacturer savings programs can lower this substantially for eligible patients	Commonly advertised in the rough range of $150–$500 per month through telehealth providers, frequently paid out of pocket
Who it tends to suit	Those with coverage or savings-card eligibility who prioritise a fully regulated, standardised product	Those without coverage facing the full list price, accepting more variability and a shifting legal picture in exchange for affordability

The pricing figures above are approximate and descriptive of what patients and telehealth providers have reported; they vary by pharmacy, region, dose, and over time, and should be checked against current quotes rather than treated as fixed. The cost gap is the single largest driver of the compounded market, and it is genuine — for an uninsured patient, the difference between a few hundred dollars and well over a thousand dollars a month is the difference between treatment and no treatment. The detail of brand pricing sits in Wegovy cost without insurance.

The salt-form question

One technical point deserves particular attention because it is where "same molecule" can stop being true. The semaglutide studied in trials and used in Wegovy is the semaglutide base. Some compounded preparations have instead used salt forms of the molecule — semaglutide sodium or semaglutide acetate. The FDA has publicly raised concern that these salt forms are different active ingredients from the base that was tested and approved, and that their safety and efficacy in humans have not been established. This is not a claim that the salt forms are necessarily dangerous; it is a statement that they have not been shown to be equivalent, which is a different and more honest thing to say.

For a patient, the practical implication is that "compounded semaglutide" is not a single, well-defined product. It may be the base form, properly prepared, at the labelled strength — functionally close to the branded molecule. Or it may be a salt form whose behaviour in the body has not been characterised the way the base has. Without knowing which, you cannot assume equivalence to the trial evidence. This is one of several reasons to ask a compounding provider exactly what is in the vial.

Dosing: a quieter source of difference

Branded Wegovy arrives in a pre-filled, single-dose pen calibrated to deliver a fixed amount, and it is escalated through a standardised titration schedule designed to keep gastrointestinal side effects manageable. That titration is not incidental. The side effects of semaglutide — nausea, vomiting, diarrhoea, constipation, early fullness — follow directly from its slowing of gastric emptying, and they are managed largely by starting low and increasing in measured steps, as set out in the GLP-1 side effects timeline. A consistent, verified dose at each step is part of what makes that schedule work.

Many compounded preparations are supplied as a multi-dose vial with a syringe, requiring the patient to draw up each dose themselves. This introduces two new variables. The first is the accuracy of the compounded concentration itself, which depends on the pharmacy's quality control. The second is measurement error at the point of use — drawing up the wrong volume from a vial is a recognised source of dosing mistakes, and there have been reports of patients inadvertently taking far more than intended when concentrations or units were misunderstood. Neither of these failure modes exists with a fixed-dose pen. None of this makes compounded dosing inherently unsafe in competent hands, but it does shift more of the responsibility for getting the dose right onto the patient and the prescriber.

The legal status: why the shortage list is the whole story

The legal basis for compounding semaglutide at scale rests largely on a specific provision: federal law generally restricts pharmacies from compounding copies of commercially available, FDA-approved drugs, but it carves out an exception when the approved drug appears on the FDA's official drug shortage list. Semaglutide spent an extended period on that shortage list as demand outstripped manufacturing capacity, and during that window large-scale compounding of the molecule was broadly permissible. That single fact is what allowed the compounded GLP-1 market to grow into what it became.

The corollary is that the legal footing is tied to the shortage, not to the molecule. As manufacturing capacity catches up and a drug is removed from the shortage list, the exception that permitted large-scale compounding narrows or closes, and pharmacies producing copies without another valid basis can become subject to enforcement. This landscape has been shifting and is best treated as genuinely in flux rather than settled. The general principle is durable — compounding copies of an available approved drug is restricted, with the shortage list as the main exception — but the specific status of semaglutide at any given moment is something to verify with a current, reliable source and your prescriber rather than to assume from an article. We describe the framework here in general, well-established terms precisely because the particulars change.

Is compounded semaglutide dangerous?

The honest answer resists both reassuring and alarming extremes. Compounded semaglutide obtained from a reputable, properly licensed pharmacy — particularly a cGMP-compliant 503B facility — and prescribed by a real clinician has been used by very large numbers of patients with a side-effect profile broadly resembling that of the branded drug. The mechanism is the same, and where the product is genuine semaglutide at the correct dose, the experience tends to track what the trials and clinical use of the brand would predict.

At the same time, the FDA and others have raised legitimate concerns. These cluster around several issues: the use of unestablished salt forms rather than the studied base; impurities or potency variation in products from lower-quality or unlicensed sources; dosing errors arising from vial-and-syringe self-administration; and the proliferation of online sellers who add ingredients such as vitamin B12 to the formulation, additions whose clinical rationale and effect have not been established. The risk, in other words, is not uniform. It depends heavily on the source. A product from an inspected 503B facility prescribed through a legitimate clinical relationship sits at one end of a spectrum; an unlabelled vial from an unverified overseas website sits at the other, and the distance between them is large.

It is also worth being clear that the branded product is not risk-free either — semaglutide as a class carries real considerations, including the gastrointestinal effects, rarer concerns around pancreatitis and gallbladder disease, and a contraindication in people with a personal or family history of medullary thyroid carcinoma. Those apply regardless of source. The compounding question is not whether semaglutide has risks; it is whether the specific product you receive has the quality assurance to keep those risks within the bounds the trials characterised.

How to evaluate a compounded provider

If cost or access leads you toward a compounded route, the questions you ask the provider matter more than the marketing they show you. A few are worth asking explicitly:

• Which pharmacy fills the prescription, and is it a 503A or a 503B facility? A 503B outsourcing facility operating under cGMP is held to a meaningfully higher standard.
• Is the product semaglutide base, or a salt form? If it is semaglutide sodium or acetate, you are not receiving the form that was studied and approved.
• Does it contain any non-standard additives such as B12, and if so, on what clinical basis?
• Has the pharmacy received FDA warning letters or state-board actions? These are matters of public record worth checking.
• Is there a genuine licensed prescriber involved — a real clinical assessment — rather than a checkout flow that issues a prescription automatically?
• What is the current legal status of compounding this drug, given the shortage-list situation at the time you are prescribed?

A provider that answers these clearly and specifically is a different proposition from one that deflects. The willingness to name the pharmacy, the form of the molecule, and the regulatory basis is itself a useful signal of quality.

Putting the difference in perspective

The reason this comparison generates so much confusion is that two true statements sit in tension. The first is that semaglutide is semaglutide — the molecule that produced about 15% mean weight loss in STEP 1 (Wilding et al., 2021), that reduced food-cue reward signalling in van Bloemendaal's imaging (van Bloemendaal et al., 2014), that the broader incretin literature has characterised in detail (Drucker, 2018), does not become a different molecule because of where it was synthesised. The second is that a finished, approved, quality-assured pharmaceutical product is more than its molecule, and the regulatory, manufacturing, legal, and dosing scaffolding around brand Wegovy is real and largely absent from much of the compounded market.

Both statements coexist. The mistake is to let one erase the other — to treat compounded semaglutide as either a perfect generic substitute or a dangerous counterfeit. For most people, it is neither. It is the same active molecule delivered through a system with less oversight, more variability, a shifting legal basis, and a much lower price. Whether that trade is a reasonable one depends on the specific source, the specific product, the specific legal moment, and the specific patient — which is exactly why this decision belongs with a clinician who knows your situation, not with a comparison table.

It also helps to remember what the medication is doing in the first place, because that frames why product quality matters at all. Semaglutide works by countering the body's defence of its prior weight — the elevated hunger and suppressed satiety signalling that Priya Sumithran's group documented persisting a year after weight loss (Sumithran et al., 2011), reinforced by the reduction in energy expenditure that Rudolph Leibel measured after weight reduction (Leibel et al., 1995) and that Manfred Müller's later synthesis placed within a coordinated homeostatic defence (Müller et al., 2018). Because that defence reasserts itself when treatment stops — the regain seen in STEP 4 (Rubino et al., 2021) and consistent with the roughly four-fifths of lost weight that returns over five years in the older diet literature (Anderson et al., 2001) — semaglutide is generally a long-term treatment, not a short course. A medication you may take for years is a medication whose quality, consistency, and legal stability are worth taking seriously, whichever route you choose. For the related comparison many patients reach for next, see Ozempic versus Wegovy and the broader background in semaglutide explained.

This article is educational and not medical, legal, or financial advice. Whether compounded semaglutide is appropriate, currently legal to prescribe, and available in your situation depends on up-to-date FDA guidance and your prescriber's assessment. Verify the current regulatory status and the pharmacy's credentials before starting, and make the decision with a qualified clinician. More on the wider landscape of these treatments sits in our GLP-1 science hub.